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Abstract:
Raman micro-spectroscopy is a non-invasive, in vitro analytical tool which is being
increasingly explored for its potential in clinical applications and monitoring the uptake,
mechanism of action and cellular interaction at a molecular level of chemotherapeutic drugs,
ultimately as a potential label-free preclinical screening and companion diagnostic tool.
In this study, Doxorubicin (DOX), a “gold standard” chemotherapeutic drug, is employed as
a model in the in vitro lung cancer cell line, A549, in order to demonstrate the potential of
Raman micro-spectroscopy to screen and identify spectroscopic markers of its trafficking and
mechanism of action. Confocal Laser Scanning Microscopy (CLSM) was used in parallel to
illustrate the uptake and subcellular localisation, and cytotoxicity assays were employed to
establish the toxicity profiles for early and late exposure times of A549 to DOX. Multivariate
statistical analysis, consisting of principal components analysis (PCA), partial least squares
regression (PLSR) and independent component analysis (ICA) were used to elucidate the
spectroscopic signatures associated with DOX uptake and subcellular interaction.
Raman spectroscopic profiling illustrates both drug kinetics and its pharmacodynamics in the
cell and associated biochemical changes, demonstrating that DOX is mainly localised in the
nuclear area, saturating the nucleolus first, within ~6hrs of exposure, before the surrounding
nuclear areas after ~12hrs, and only accumulates in the cytoplasm after 48hrs. PLSR over
varying time intervals enables identification of DOX-DNA binding at early stages of
exposure (0-12hrs), while regression over the longer time periods (24-72hrs) reveals
spectroscopic signatures associated with the metabolic cellular response.

Keywords: Raman micro spectroscopy, Confocal Laser Scanning Microscopy, Doxorubicin,
cytotoxicity, long and short time exposure, Multivariate Analysis.

1. Introduction:

Doxorubicin (DOX), a cell cycle non-specific chemotherapeutic agent, is one of the two first
anthracycline antibiotics isolated from Streptomyces peucetius (1) and among the most
widely used chemotherapeutic agents, despite its numerous side effects, (2, 3) and is highly
effective in treating different types of cancers, from leukaemia, thyroid, and lung to many
other neoplasia, especially metastatic and invasive ones. (3-6) The accepted mechanisms of
action of DOX are complex and not fully understood, and include the interaction (i) with the
cellular nuclear area, consisting of DNA intercalation, cross-linking, binding and alkylation,
inhibition of topoisomerase I and II and RNA polymerase, all inducing DNA damage,
inhibition of DNA replication and protein synthesis (rRNA transcription inhibition), as a
consequence, leading to nucleolar disruption and cellular apoptosis (7) and (ii) with the cell
membrane and mitochondria, resulting in generation of reactive oxygen species leading to
direct membrane damage and oxidative stress, responsible for the major DOX side effect,
cardiomyopathy.(3, 8-10) DNA remains the main target of cancer therapeutics, whereby
induction of DNA damage initiates a cascade of events that determines cellular apoptosis.
DNA damage level and repair, by expression of anti-apoptotic proteins such as bcl-2 and
resistance to apoptosis, are the main processes involved in carcinogenesis and in the response
of cancer cells to cancer chemotherapy.(11, 12)
Apoptosis, known as programmed cell death, plays an important role in the internal
environmental homeostasis and is closely associated with the development of cancer and in
chemotherapy, by implication, of drug-induced cell apoptosis.(13) One of the pathways
leading to apoptosis disruption and tumour development is the nucleolar stress pathway.(14)
In fact, the nucleolus, known also as a ribosome factory, is the most prominent structure
inside the nucleus, acting as a central integration of signalling pathways and performing
numerous functions such as production of ribosome subunits, RNA editing and cell cycle and
playing an important role in cancer development by dysregulation of its functions. (15-17)
Due to its fundamental contribution in cancer proliferation, the nucleolus is the target for
chemotherapeutic drugs such as Actinomycin D, which inhibits rRNA synthesis, Cisplatin
which interferes with RNA Polymerase I in the nucleolus decreasing rDNA transcription, 5fluoruracil which targets rRNA processing, DNA/RNA synthesis and DNA repair and DOX,
which is known to disrupt nucleolar morphology and decrease rDNA transcription.(14, 18) It
has also been shown in previous Raman spectroscopic studies that this sub-nuclear region is
responsible for the discrimination between cancer cell lines.(19)

Among the most common cancers worldwide, lung cancer is by far the highest cause of
cancer-related death and has a 5-year survival of 15% .The main treatments of lung cancer
are chemotherapy and radiotherapy, but these approaches have serious side effects and drug
resistance is often developed during treatment.(20) Thus, a better understanding of the
mechanism of drug action and the cellular responses at the pre-clinical step is crucial to
improve patient survival. To this end, Raman micro spectroscopy, a non-invasive powerful
label-free in vitro screening tool, is presented as the ideal candidate due to its ability to detect
chemical, biological and physical changes of biomolecules at subcellular level and provide a
molecular fingerprint of the sample of interest, in this case cancer cell physiology, at a subcellular level, during chemotherapeutic treatment.(21-24)
Raman micro spectroscopy has attracted considerable attention over the last few years in the
pharmaceutical field to aid in areas such as the drug discovery process, quality control during
industrial manufacturing and detection of counterfeit products, (23, 25, 26) and well as its
possible clinical applications. (27, 28) Its potential as a screening technique either for normal
and cancer cell discrimination or in chemotherapeutic and cellular process screening has been
demonstrated.(19, 29)
Therefore, it can be developed as a companion diagnostic tool, providing details about drug
efficacy and safety, as detailed in the US FDA guidance document issued in August 2014,
which defines such a tool as an in vitro diagnostic device that provides information that is
essential for the safety and efficacy of a corresponding therapeutic product.(30, 31)
The demonstration of Raman micro spectroscopy as a companion diagnostic for screening
and analysis of commercial chemotherapeutic agents could be of significant importance in
cancer research and especially in pre-clinical in vitro screening, a concept introduced by the
US National Cancer Institute (NCI) in 1955 and providing screening models and supports to
research, as a model which accurately predicts drug efficacy accurately at a molecular level,
clinical activity and pharmacodynamics and kinetics. (32, 33)
Previously, DOX, routinely used for lung cancer therapy, was employed with A549, a nonsmall lung cancer cell line, and Raman analysis of the distribution of the drug in the cell, and
the changes in the cellular spectroscopic signatures was performed, at a fixed point in time
(24hrs). (29)
In the present paper, investigations were extended to look at the evolution of the responses, in
order to track the drug reactions for early and late stages exposure, globally understand the
mechanism of action and monitor the subsequent cellular behaviour using Raman microspectroscopy. The study demonstrates the potential of Raman Spectroscopy to monitor the

drug uptake and the cellular responses at a subcellular level, but also elucidate details of the
pharmacodynamics and drug cellular kinetics of the clinically prescribed drug.

2. Materials and methods:
2.1.Materials:

A549 human lung adenocarcinoma cells with the alveolar type II phenotype were obtained
from ATCC (Manassas, VA, USA).
Doxorubicin hydrochloride® powder (Sigma Life Sciences, Ireland) was diluted in1mL sterile
water to the required concentration (17.25 mM).
Alamar blue (AB) (10X ready to use solution) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide (MTT) were obtained from Sigma Aldrich, Ireland.
For cytotoxicity assays, an AB/MTT solution, 1.5mL of AB and 3 mL of MTT stock solution
(2.5mg/mL, 25mg MTT/10mL PBS) in 30mL of fresh medium was prepared prior to the
tests.

2.2.Cell culture

A549 cells were cultured in DMEM (with 2 mM L-glutamine) with 10% foetal bovine serum
(FBS) at 37°C in a humidified atmosphere containing 5% CO2 and cells were split every two
days to maintain ~60% confluence.
For Confocal Laser Scanning Fluorescence Microscopy (CLSM) and Raman micro
spectroscopic analysis, cell number was determined using a Beckman Coulter Particle Count
and Size Analysis® Z2Cell Counter.

2.3.Cytotoxicity assays:
AB and MTT assays were performed in 96 well plates and a total number of 1x105/25mL,
1x104/25mL and 5x103/25mL cells, respectively for 0-24hrs, 48hrs and 72hrs DOX exposure,
were used to seed three plates each. After 24hrs incubation, plates were washed with
phosphate buffered saline solution (PBS) and DOX was added in a concentration range from
0 µM (as a control) to 50 µM.
AB and MTT assays were both measured with a Cytotox SpectraMax ®M3 plate reader using
Soft Max® Pro6.2.2 software. After incubation in DOX, plates were washed with PBS and

100µL of AB/MTT solution were added to each well. Plates were then incubated for 3 hours
and AB fluorescence was measured first in the plate reader using 540nm excitation and
595nm emission, then the medium was removed, the plates were washed with PBS and
100µL of DMSO (Dimethyl sulfoxide) were added in each well. MTT absorbance was read at
570nm.
All cytotoxicity assays were made in triplicate and repeated three times and viability data was
fitted by a four parameter Hill equation analysis using SigmaPlot 10.0, to yield values of the
mean inhibitory concentration, IC50.

2.4.Confocal Laser Scanning Fluorescence Microscopy:
Approximately 1 x 104 cells were allowed to attach on uncoated glass bottom Petri dishes
(MatTek Corporation, USA) for two hours, after which they were covered with cell culture
medium. After 24hrs incubation, the medium was removed and samples were rinsed twice
with sterile PBS, new fresh medium containing DOX corresponding to the inhibitory
concentration, IC50, determined by cytotoxicity assays for each time point (48 and 72hrs) and
adjusted to the cell number (Table 1), was added and cells were incubated for a further 48hrs
and 72hrs separately. For short time exposure, cells were incubated with the inhibitory
concentration, IC50 determined previously for 24hrs, and samples corresponding to each time
point, 2, 6, 12 and 24hrs were prepared separately. After incubation, samples were rinsed
twice with sterile PBS, fixed in formalin (4%, 15mn) and kept in PBS for imaging. Control
samples without exposure to DOX were also prepared in parallel, and incubated for 2, 6, 12,
24, 48 and 72 hrs.
CLSM images were recorded using an inverted Zeiss LSM 510 confocal laser scanning
microscope equipped with a x60 oil immersion objective. DOX fluorescence was excited
with an argon ion laser at 488 nm, and the emission was collected at 530 nm.

2.5.Raman micro spectroscopy:
Cells (~ 1x 104/window) were seeded and incubated on CaF2 windows (Crystan Ltd, UK) for
24 hrs for both control and exposure to DOX. Medium was then removed and samples were
rinsed twice with sterile PBS and covered with DOX at each corresponding IC50 inhibitory
concentration (IC50 (24hr) for 2, 6, 12, 24 hr exposure, IC50 (48hr) and IC50 (72hr)) which is
normalised according to the cell number used (~1x 104/window) (Table1). The 24hr IC50 dose
was initially chosen, based on previous studies (12), in order to monitor the kinetics of the

uptake of DOX at earlier times. This dose was reduced for 48hr and 72 hr exposures, as it
would be too toxic at the longer exposure times.
After each incubation period (2, 6, 12, 24, 48 and 72 hrs), cells were washed twice with
sterile PBS and fixed in formalin (4%, 15min).
A Horiba Jobin-YvonLabRAM HR800 spectrometer with a 785nm, 300mW diode laser as
source (~100 mW at the sample), Peltier cooled 16-bit CCD, 300 lines/mm grating and 100
μm confocal hole, was used for this work. Spectra were acquired in the range from 400 cm -1
to 1800 cm-1 using a x100 objective (LCPlanN, Olympus), in dry conditions, for 30s twice,
from three cell locations: cytoplasm, nucleus and nucleolus, to finally produce a data set of
30 points per cell location for each time point, 2, 6, 12, 24, 48 and 72hrs after DOX exposure
and for control cells, over a total of 210 cells corresponding to a total data set of 630 spectra.

2.6.Data analysis:
Raman spectral pre-processing and analysis were performed in Matlab 2013 using algorithms
developed in house. Prior to analysis, background was subtracted using a NCLS (nonnegatively constrained least squares) algorithm and spectra were subsequently smoothed
(Savitsky-Golay filter 3th order, 11 points), baseline corrected (fifth order polynomial) and
vector normalised.
Principal components analysis (PCA) was employed as an unsupervised multivariate
approach to analyse data and the effects of doxorubicin in each cell localisation. The order of
the PCs denotes their importance to the dataset and PC1 describes the highest amount of
variation.(34)
Partial least squares regression (PLSR) was employed to track the temporal and dose
dependent evolution of the spectral signatures in the subcellular regions. PLSR is a statistical
regression technique which reduces the dimensionality of the data and correlates information
in an X data set matrix to the matrix of a Y data according to the equation Y= XB + E, where
B is a matrix of regression coefficients and E is the regression residual. In this work, the Xmatrix is represented by the Raman spectra and the Y-matrix is consisted of values of the
DOX concentration inside the cells, and the time evolution.(35-37)
The percentage of variance explained in the response variable (Y) as a function of the number
of components was calculated using 10-fold cross validation and from a plot of the percent of
variance explained function of number of components, the majority percentage of variance
(above 90%) was found to be explained by the first 3 components.

The regression coefficients obtained by PLSR of Raman data regressed separately against
DOX cellular concentration and time evolution were plotted and analysed. As a function of
frequency, the co-efficients illustrate the spectral features which are influenced by the
intracellular interaction of the DOX and the resulting metabolic changes.
Independent component analysis (ICA), a signal-processing technique, was also employed as
an extension to PCA. ICA is an unsupervised statistical technique able to identify latent and
statistically independent variables called independent components and corresponding to the
pure signal underlying the observed signal and to interpret their different contributions. In
the case of Raman micro spectroscopy, ICA can be used to identify and extract principal
spectral contributions such as those from substrate, using the same number of ICs
(independent components) as PCs which is three components, which can then be removed or
studied in their own right.(12, 38-40) The first independent component (IC1) explains the
highest percentage of variance and was used to further examine the temporal evolution of the
spectral signatures.

3. Results:
3.1. Cytotoxicity assays:

The cytotoxicity of A549 cells to DOX exposure using both the AB and MTT assays for
24hrs has been previously reported (29), indicating an IC50 of 0.42 ± 0.06μM and 0.55 ±
0.16μM for AB and MTT, respectively. Figure S1 of the supplementary information shows
the dose dependant cytotoxicity of DOX after 48hrs (Figure S1A) and 72hrs (Figure S1B)
exposure, for the A549 cell line, according to the AB and MTT in vitro cytotoxicity assays.
Viability is expressed as % compared to control (non-exposed healthy cells), and the error
bars indicate the standard deviation of six independent replicate measurements. For both in
vitro assays and for all times exposure, a partial loss of cell population viability is observed.
The AB and MTT assays for the A549 cell line show similar responses for late time exposure
(48 and 72hrs) but slightly different ones for 24hrs. However, the IC50 values for 48 hrs
exposure for A549 cells are comparable and were determined to be 0.30± 0.04μM and 0.31±
0.05μM for AB and MTT, respectively. Similar behaviour was found after 72hrs treatment,
characterised by IC50 values of 0.29± 0.02M and 0.27± 0.02M, respectively for AB and
MTT.

The MTT assay is a reflection of mitochondrial activity while the AB assay is the expression
of general cellular metabolism. The somewhat greater sensitivity of MTT compared to AB at
the early stages is consistent with a mechanism of interaction which induce an early
apoptosis.(41, 42) Nevertheless, since the mechanisms and cellular effects for the long time
exposures of 48 and 72hrs will be compared to those for shorter exposures 0-24hrs, the IC50
determined by the MTT assay was used throughout the study for comparability purposes and
Figure 1 shows the dose dependant cytotoxicity for those time points.

Figure 1: MTT in vitro dose dependent cytotoxicity assays of DOX to A549 cell line for
short (0-24hr) and long exposure times (48hrs, 72hrs).Viability is expressed as % compared
to control, and the error bars indicate the standard deviation of six independent replicate
measurements
For Raman micro spectroscopy and Confocal Laser Scanning Fluorescence Microscopy, the
DOX dose used was scaled to cell numbers, according to a linear relationship between MTT
response and cell number, using each corresponding IC50 and Table 1 shows the different
concentrations used.(43-45)
Table 1: IC50 determined by the MTT and corresponding dose used for 104 cells.
Exposure time (hrs)

0-24

48

72

IC50(μM)

0.55± 0.16

0.31± 0.05

0.27± 0.02

DOX Concentration (μM)

13.75

77.5

135

3.2.Confocal Laser Scanning Fluorescence Microscopy:

Confocal Laser Scanning Fluorescence Microscopy (CLSM) was employed to visualise and
confirm the DOX intracellular internalisation and subcellular localisation. Figure 2 illustrates
the images for different DOX exposure times, from 2hrs to 72hrs; clearly demonstrating that
DOX is predominantly accumulated in the nuclear region at all time points. The DOX nuclear
accumulation is obvious even after only 2hrs, suggesting that this commercial drug is
trafficked straight to the nuclear area without any accumulation in the cytoplasm up to 24hrs.
Some trace amounts do appear in the cytoplasm at 48 and 72hrs, consistent with the onset of
a late cytoplasmic DOX mechanism of action associated with oxidative stress as a result of
reactive oxygen species production.(12) Compared to healthy control cells, exposed cells
appear smaller in size and round or oval in shape and exhibit noticeable fragmentation of
nucleoli within the nucleus, with tightly packed cytoplasm and membrane blebbing. All these
morphological changes confirm that cells are undergoing apoptosis. (16, 18, 29, 46)

1.

2.

3.

4.

5.

6.

Figure 2: Confocal Laser Scanning Fluorescence images of A549 cells after DOX exposure
and corresponding controls: 1.2hrs DOX exposure, 2.6hrs DOX exposure, 3.12hrs DOX
exposure, 4.24hrs DOX exposure, 5.48hrs DOX exposure and 6.72hrs DOX exposure

3.3.Raman micro spectroscopy:

Raman micro spectrosopy has previously been demonstrated to be cabable of tracking DOX
inside the cellular compartments and differentiating between its different mechanisms of
action and the cellular responses due to drug treatment at a fixed timepoint of 24hrs exposure.
In order to further investigate the subcellular responses and to track the drug pathway, Raman
profiles from the three subcellular compartments, nucleolus, nucleus and cytoplasm, were
analysed at shorter timescales of 2, 6 and 12hrs at the 24hr IC50 concentration, and at the
longer exposure times of 48hrs and 72hrs, at the IC50 concentration, adjusted to the cell
number, of these time points, as determined using the MTT assay (Figure 1, Table 1).

A.

B.

C.

D.

Figure 3: Raman spectra after background subtraction, baseline correction and vectornormalisation of A. Doxorubicin dissolved in sterile water and mean spectra of A549 cell line
for 0, 2, 6, 12, 24, 48 and 72hrs of B. nucleolus C. nucleus and D. cytoplasm

Figure 3 shows the mean spectra for each time point of the three cellular localisations,
namely the nucleus, the primary location of DNA, the nucleolus, a sub-compartment of the
nucleus, which contains RNA and small amount of DNA, and the surrounding cytoplasm

containing the cytoskeleton, a framework of protein filaments, all protected by the plasma
membrane.(47, 48)
In general, nucleic acids can be identified by peaks characteristic of nucleotide and sugarphosphate backbone vibrations (24) and the main bands are for example at 785 cm-1, assigned
to cytosine and thymine (DNA/RNA) and DNA backbone O–P–O stretching, 813 cm-1,
related to RNA O–P–O stretching, 830 cm-1, corresponding to DNA B form O-P-O asymetric
stretching and 1095cm-1, assigned to DNA PO2− symmetric stretching. Protein signatures are
dominated by peaks related to Amide III and Amide I vibrations, between 1230-1280cm-1 and
1640-1695 cm-1, respectively, and amino acids containing phenyl groups, such as
phenylalanine peaks at for example 1005 and 1030 cm-1, tryptophan at 760 cm-1and tyrosine
at 645, 853 and 877cm-1. Lipids are predominatly represented by peaks at 700-720 cm-1,
related to C–C–N+ symmetric stretching in phosphatidylcholine, 1303 cm-1 assigned to C-H
vibration and between 1410 and 1495 cm-1corresponding to C-H deformation.(24, 29, 49)
Since the Raman spectra are characteristic of the molecular structure, any changes to that
structure, for example after chemotherapeutic treatment, can be detected and monitored.
As an illustration, for both nucleolar and nuclear regions (Figure 3B and C), an obvious shift
towards lower wavenumbers of the band at 1095 cm-1confirms again that DOX is able to bind
to DNA externally, starting from the early stages of exposure (29), and a decrease of the band
at 785 cm-1 indicates a progressive DNA/RNA denaturation, while in the nuclear region, there
is a decrease in the features at 830 cm-1 and, in the nucleolar area, an almost complete
disappearance of the band at 813 cm-1, potentially due to cessation of DNA replication as a
consequence of DNA denaturation and fragmentation.(50, 51) In the cytoplasmic area (Figure
3D), a slight increase in features at 1065 and 1080 cm-1is observed, corresponding to protein
C-N stretching, which may correspond to an increase of signaling proteins in cells going
under apoptosis.
It is notable that, for all cellular regions and over the time course, there is an increase in the
principle DOX features (Figure 3A, indicated by the highlighted regions in Figure 3 B, C and
D) at 440 and 465 cm−1, respectively corresponding to C–C–O and C–O vibrations, and at
1215 and 1245 cm−1, related to C–O–H and C–O. Notice, however, that DOX features only
appear in the cytoplasm starting from 48hrs exposure. Similar observations were found in
CLSM images (Figure 2), confirming the primary localisation of DOX in the combined
nuclear area for all time points before 48hrs treatment.
In order to examine further the DOX cellular pathway, PCA of exposed cells versus control
was employed and a clear separation occured according to PC1 for all time points compared

to control, as previously demonstrated for 24hr exposure (29) (data not shown). The
evolution of DOX peak intensities at 440, 465, 1215 and 1245 cm-1, corresponding
respectively to C-C-O, C-O, C-O-H and C-O vibrations of the DOX molecule, in the loading
of PC1 was analysed, as shown in Figure 4. The intensity is expressed as a percentage of the
highest value of each respective band in the three subcellular regions.

Figure 4: Evolution of DOX Raman bands at 440, 465, 1215 and 1245 cm-1as a function of
time for the A549 cell line for each cellular compartment, nucleolus, nucleus and cytoplasm.
Intensities are expressed in percentage according to the maximum value for each band over
the three cellular compartments and standard deviation corresponds to the spectral variations
of each band.

It is obvious that there is a progressive increase of DOX intracellular concentration until a
plateau is reached after 6-12hrs exposure and DOX is seen to accumulate in the nucleolus
first, then the nucleus and after 48hrs appears in the cytoplasm. Since the bands at 1215 and
1245 cm-1 can be influenced by the proximity of protein features,further analysis was
focused on the two bands at 440 and 465 cm-1. Notably, according to these two DOX Raman
bands, there is more DOX in the nucleolus than the nucleus for 2, 6 and 12hrs exposure, with
a maximum at 6hrs. These observations are consistent with a mechanism of DOX being
trafficked straight to the combined nuclear area, after a passive diffusion to the cells due to its

high lipophilicity, binds to proteasomal then translocates into the nuclear area,via nuclear
pores, where it dissociates from the proteasome complex and binds to DNA with hight
affinity, (1, 7) a larger amount accumulating in the denser nucleolar area, which saturates
more rapidly. Accumulation in the cytoplasm is only evident after 48hrs, confirming previous
studies showing that the intracellular DOX is primarily accumulated in the nuclear area, at
short exposure times, and that the main mechanism of action is one of DNA intercalation,
interfering with both DNA and RNA polymerase and as a consequence inducing DNA
replication and RNA transcription blockage.(7, 52) The observed plateau in the nuclear and
nucleolar regions is more notable, given that the doses for 48 and 72hrs were increased to the
respective doses of 77.5M and 135M, respectively, compared to 13.75M for 24hrs (Table
1). Nevertheless, it is clear that the DOX concentration inside the combined nuclear regions
becomes approximately constant after ~24hrs exposure, after which DOX begins to
accumulate in the cytoplasm due to nuclear membrane loss of integrity.(46, 53)
The behaviour is consistent with saturation of nuclear binding sites after a certain time and
any additional drug taken up by cells accumulates in the cytoplasm. (54, 55)
In order to track the cellular changes associated with the progressive uptake of DOX in the
subcellular regions, PLSR was employed, and spectra were regressed against time,
progressively increasing the time interval from 0-6 to 0-72hrs. The resultant regression coefficients for the nucleolar and nuclear region are shown in Figure 5.
In the case of the regression as a function of time for the nuclear region (Figure 5B), the coefficients over the period 0-6hrs and 0-12hrs are almost identical, whereas regression beyond
this period results in significant changes to the regression co-efficients. In the case of the
nucleolar spectral data (Figure 5A), such significant changes in the regression co-efficients
are evident on progressing from 0-6hrs to 0-12hrs, and beyond. For both cellular regions, the
time points after which the regression co-efficients begin to change significantly co-incide
with those of the onset of saturation of the DOX related spectral features in Figure 4,
indicating that the regression over the timepoints up to saturation identifies spectral features
associated with the initial drug mechanism of action, before saturation, after which the
cellular responses become evident.

A.

B.

Figure 5: Regression coefficients obtained by PLSR analysis as a function of time over
progressive exposure time intervals (T) for A. nucleolus and B. nucleus. The dashed
horizontal line indicates the zero-point for T: 0-6hrs and the other co-efficients are off set for
clarity.

In the T:0-6hrs regression co-efficients for the nucleolar region (Figure 5B), notable positive
DOX features are observed at 440-465 cm-1 and 1215-1245 cm-1, indicating the progressive
accumulation of DOX, as shown in Figure 4. A concomittent decrease in cellular features
corresponding to nucleic acids is observed, at 785 cm-1 (cytosine and thymine, DNA
backbone O–P–O stretching), 813 cm-1 (RNA O–P–O strecthing), 853 cm-1 (tyrosine ring
breathing), 109 5cm-1 (DNA backbone O–P–O stretching), 1270 cm-1(RNA uracil and
cytosine ring stretching), 1300 cm-1(RNA cytosine and adenine ring stretching),1376 cm-1
(thymine), and 1577 cm-1 (adenine and guanine),representing a modification of their cellular
content due to blockage of DNA replication and transcription as a result of DOX treatment,as
well as a change in the profile of peaks at 1410,1445 and 1491 cm-1, indicating lipid
denaturation, probably of the surronding cytoplasmic membrane and features at 1005cm-1
(phenylalanine), 1607cm-1(tyrosine and phenylalanine ring vibration C=C) and 1673cm-1
(Amide I), indicating a change in nucleolar proteins.(21, 24, 29, 49, 51, 56, 57)
Over the regression period T:0-12hrs, although the overall profile of the co-efficients is
distinct compared to that of the nucleolar region, similar spectral changes are observed for the
nuclear region, in addition to those at 830 cm-1 (O–P–O asymmetric stretching, DNA B
form), 881 cm-1 (Deoxyribose ring breathing) and 1340 cm-1 (adenine and guanine).
The nucleolar and nuclear region are composed of similar biochemical constituents, and
similar changes to these are prominent in the regression co-efficients of both regions.
However, the distinctly different profiles in Figure 5A (Nucleolus T:0-6hrs) and Figure 5B
(Nucleus 0-12hrs) indicate different rates and degrees of interactions with the constituent
conponents in the different subcellular regions.
Notably, as shown in Figure S2, for each cellular region, the co-efficients for regression
against the internalised dose, as determined by the peak intensity in the loading 1 of PCA
control versus exposed cells (Figure 4), are largely invariable, and almost identical to the time
dependent regression co-efficient profile (T:0-6hrs for nucleolus and T:0-12 for nucleus)
(Figure 5) up to the saturation point (Figure 4)
So, for both nucleus and nucleolus and for both regression against short time exposure and
DOX cellular concentration, a notable decrease in DNA and RNA features for example at
728, 785-795, 813, 1376 and 1486 cm-1 is evident. However, the changes to the nucleic acid
features over this initial period are much more pronounced and more rapid in the nucleolar
region than in the nucleus itself.
Following the initial DOX binding interactions in the nucleoli and then nuclear regions of the
cell, and although the DOX concentrations saturate in the nuclear regions after ~12 hrs,

(Figure 5), the cellular features continue to evolve as a function of time, in response to the
action of the drug. This can be clearly seen in Figure 5, but, in order to differentiate the
spectral characteristics of the initial chemical interactions of the drug from the subsequent
cellular responses, the spectral evolution over the time period 24-72hrs was regressed against
time and internalised cellular DOX concentration. Notably, in the PLSR analysis of nucleolus
and nucleus regressed against time over the later stages, shown in Figure 6 (IA and IIA), only
cellular features appear and no DOX features are apparent, which confirms the fact that after
certain time, DOX reaches a constant concentration inside the nuclear regions of the cells, as
evidenced by the plateau in Figure 4.
As seen in Figure 6I, for the nucleolar regions at late stages (24, 48 and 72hrs), there is an
increase in protein features at 447, 454, 1005 cm-1(phenylalanine), 853 cm-1(tyrosine ring
breathing), 1207cm-1(phenylalanine, tryptophan and tyrosine), 1230 cm-1(Amide III), and
1660 cm-1 (Amide I), consistent with an afflux of anti-apoptotic protein trying to repair DNA
and avoid apoptosis.(12) There is also a significant decrease in DNA features at 785cm-1
(cytosine and thymine), 830 cm-1(DNA B form), 1220 cm-1(adenine and thymine) and 1577
cm-1 (adenine and guanine), representative of DNA depletion and denaturation due to a long
term effects of DOX.
Similar increases in protein features as a function of time in the later stages of exposure is
apparent in the nuclear area, as shown in Figure 6 II, in addition to a progressive decrease in
DNA features at 785, 795 cm-1(cytosine and thymine), 1095 cm-1 (DNA backbone O–P–O
symmetric stretching), 1220 cm-1 (adenine and thymine), 1376 cm-1 (thymine), 1577 cm-1
(adenine and guanine), and a lipid denaturation indicated by peaks at 700-715-720, 1127 and
1450 and 1491 cm-1.

I.

II.

Figure 6: Regression coefficients obtained by PLSR analysis of long term DOX exposure
over the time period (24-72 hours) of I.nucleolus and II. nucleus (A) regressed against time
and (B) against DOX concentration inside cells determined by the peaks intensities of the
band at 465 cm-1 in loading 1 of PCA exposed cells versus control.

In both nucleolar and nuclear regions at prolonged exposures, a notable increase is observed
in features at 1047 cm-1(RNA P–O stretching, sugar phosphate –C–O–stretching), and 1270
cm-1(RNA Uracil and Cytosine ring stretching), while that at 1376 cm-1(thymine) is seen to
decrease.The continued changes to RNA features in both nucleolus and nucleus over the later
time period could be explained by a decrease of RNA as a consequence of DNA denaturation
and blockage of its replication but the concomitant increase in some RNA peaks could be due
to nucleolar fragmentation, resulting in RNA spread into the nucleus. (16, 58)
In addition to spectral features which may be characteristic of DNA and RNA depletion and
nucleolar fragmentation, there is an increase in both lipid and protein features, at 645 cm-1 (CC

tyrosine),

715

cm-1

(choline),

720

cm-1

(C–C–N+

symmetric

stretching

inphosphatidylcholine), 760 cm-1(tryptophan ring breathing), 853-877 cm-1 (tyrosine ring
breathing), 1005 cm-1(phenylalanine), 1127 cm-1 (C-N stretching), 1410-1445 cm-1 (CH2
vibrations), 1607cm-1 (tyrosine and phenylalanine ring vibration C=C), and 1656-1673 cm-1
(Amide I) (Figure 5 and 7), as a cellular response to DOX exposure,which may be associated
with the efflux of anti-apoptotic protein and a synthesis of lipidic vesicules as a way to
remove DOX to the extracellular environment. (29, 56, 59, 60)
The increase in phenylalanine in both nucleolar and nuclear regions seems to be a marker of
the late apoptosis stage, at which point nucleolar fragmentation is complete, leaving an empty
space with only cellular membrane (Figure 6).(57, 61)
Thus, it appears that regression against DOX cellular concentration shows the initial DOX
accumulation inside the cells, its nuclear binding and its subsequent effects, including DNA
damage, while regression against varying time intervals can elucidate and differentiate both
the initial DOX mechanism of action and its cellular effects, such as depletion in DNA, RNA
and proteins leading to apoptosis and the cells reactions to those DOX effects which could be
a marker of any cellular-drug resistance.

Figure 7: Regression coefficients obtained by PLSR analysis of cytoplasm (A) regressed
against time full range and (B) against DOX concentration inside cells determined by peaks
intensities of band at 465 cm-1 in loading 1 of PCA exposed cells versus control

Figure 7 shows the PLSR of the cytoplasmic region of the cell against time and DOX cellular
concentration. In both regression co-efficient profiles, there are obvious DOX features at 440465cm-1 and 1215-1245 cm-1, in addition to cellular ones related to proteins and lipids, for
example at 524 cm-1, corresponding to phosphatidylserine externalization as an indicator of
cell signalling in apoptosis (62, 63), 538 cm-1 related to cholesterol ester, which increases due
to alteration of the function of integral endoplasmic reticulum membrane proteins and is a
marker of apoptosis (64, 65), 576-776 cm-1 (phosphatidylinositol) related to membrane
trafficking, 645-830-853cm-1 (tyrosine), 749-760 cm-1 (tryptophan), 940 cm-1 (C-C stretching
of protein), 1085 and 1128 cm-1 (C-N stretch), 1268 cm-1 (Amide III), 1410-1450cm-1 (CH2
deformation), 1607cm-1 (C=C phenylalanine and tyrosine), 1640-1694 cm-1 (Amide I of
different conformational forms indicating a protein denaturation). (56, 59) Features at 6451005 cm-1(C-C phenylalanine) and 1030cm-1(C-H phenylalanine) indicate a change in the
protein environment due to DOX exposure (50), while changes in the profile of the band at
1450cm-1 (C-H deformation) and around 1303cm-1 (lipid C-H vibration) (59) are consistent
with a lipid structure denaturation by peroxidation due to ROS production under DOX
treatment. (13)

4.Discussion:

Raman spectroscopic microscopy can clearly track the kinetics of the uptake and
accumulation of the chemotherapeutic drug DOX at a subcellular level in vitro, and can
differentiate the biochemical responses associated with the subcellular regions of nucleolus,
nucleus and cytoplasm, both in terms of the mechanisms of action, and the subsequent
cellular metabolic responses. In both cases, the spectroscopic signatures are a complex
combination of the contibutions of the many biomolecular responses and their evolution
requires the use of multivariate regression analysis. Independent Components Analysis can be
used to extract the primary contributions of this combinatorial response, at each timepoint, as
shown in Figure S3, for each exposure timepoint for (A) nucleolar and (B) nuclear regions of
the cell, again highlighting the multivariate nature of the spectral responses.
The evolution of selected features can be plotted against time, and correlated with that of the
uptake and accumulation of the DOX in the different subcellular regions, as well as each
others, as shown in Figure 8. The intensities of DNA, RNA, proteins and lipids bands was
determined by ICA after DOX subtraction, as ICA can identify spectral cellular components
contributions independently while DOX band was determined by PCA control vs exposed
cells (Figure 4).
The interaction with DNA and RNA in both the nucleolar and nuclear regions of the cell as a
function of time is apparent in Figure 8A, showing the evolution of DNA features at 830 cm-1
(O–P–O asymmetric stretching, DNA B form) and 881cm-1 (Deoxyribose ring breathing) and
RNA features at 1270 cm-1 (RNA Uracil and Cytosine ring stretching) and 1300 cm-1 (RNA
Cytosine and Adenine ring stretching). Notably, the feature at 785 cm-1 (Cytosine and
Thymine, DNA backbone O–P–O stretching), can be ascribed to either DNA or RNA.

A. (i)

(ii)

B. (i)

(ii)

Figure 8: A. Evolution of DOX (465 cm-1) and selected RNA (785, 1270, 1300 cm-1) and
DNA (785, 830, 881cm-1) Raman bands as a function of time for the A549 cell line for each
nuclear cellular compartment, (i) nucleolus and (ii) nucleus. B. Evolution of DOX (465 cm-1)
and selected protein (1005, 1230, 1660 cm-1), lipid (1450 cm-1) Raman bands as a function of
time for the A549 cell line for each nuclear cellular compartment, (i) nucleolus and (ii)
nucleus. Intensities are expressed in percentage according to the maximum value for each
nuclear area and standard deviation corresponds to the spectra variations for each band.

The changes in the nucleic acid bands in the nucleolar region are concomitant with the
accumulation of DOX, and the changes cease when the accumulation of DOX saturates,
associating these with an instantaneous interaction with the biochemical components, and
therefore the initial DOX-DNA binding. (66, 67) In the nucleus, the equivalent changes occur
more slowly, but also appear to saturate once the accumulation of DOX in the nucleus has
saturated. A further observation is that the relative changes in the nucleic acid spectral
features are much stronger in the nucleolus than in the nuclear region. Moreover, the same

kinetics of evolution were found using PLSR, highlighting that the same cellular features,
mainly DNA and RNA are affected by DOX in both nucleolus and nucleus, due to interuption
of DNA replication and RNA transcription, but at different rates and intervals. DOX affects
the nucleolus instantaneously, and once saturation of DOX is reached at 6hrs, an almost total
reduction of DNA and RNA features to~20% has occured. In the case of the nucleus, this
decrease is slower even after saturation at 12hrs and reaches only ~40% of the initial levels.
It is also obvious that, after DOX exposure, proteins and lipids (Figure 8 B) start decreasing
as a consequence of RNA/DNA alteration, and then increase at later stages of the cellular
responses, which corresponds to an increase of anti-apoptotic proteins and a synthesis of
lipids vesicules as a cellular reaction to the chemotherapeutic treatment, after which, cells
initiate late apoptosis corresponding to a point of no return.
Previous studies have investigated the DOX nuclear accumulation by using either DOX
fluorescence or indirect labeling techniques, showing an intimate relationship between DOX
nuclear accumulation and its cellular concentration.(68) However, those approaches present
some limitations, as DOX fluorescence can be influenced when it intercalates with DNA and
the mechanism of action of dyes used to probe, for example DNA content (55), are unclear
and can interfere with the process itself.(69, 70) No relationship between nuclear DOX
accumulation and its cellular effects has been clearly defined. In contrast, using Raman micro
spectroscopy as an in vitro label free tool to investigate drug kinetics and pharmacodynamics,
coupled with multivariate data analysis, shows the DOX cellular distribution, interactions and
effects.It appears that the early stage responses are dominated by the kinetics of the
chemotherapeutic drug accumulation, principally in the nucleolar region, and by the DOXDNA interaction. Notably, the observed changes in these early stages are predominantly
associated with RNA, rather than DNA, changes to which become more prominent in the
interactions in the nuclear region. At later stages, when the localised DOX concentration has
reached the saturation point, the cellular response to DOX treatment becomes prominent.
Saturation of the nucleolar region prior to the nuclear highlights again the importance of this
subcellular region, not only in the cancer process but also in chemotherapy and cellular
resistance, since it is the first to be targetted by DOX and as a consequence the first to react to
drug exposure, followed by the nucleus and finally by the cytoplasm after 48hrs exposure.
The observation that appreciable accumulation of DOX in the cytoplasm is only apparent
after such prolonged exposure times may have implications on the relative contributions of
alternatives routes towards cell death based on oxidative stress in the cytoplasm.(71)

5. Conclusion:

The Food and Drug Administration classifies DOX as one of the most effective
chemotherapeutic drug worldwide used for the treatment of various cancers.(1, 7)
Nevertheless, it presents serious clinical side effects and its full mechanism of action is still
not completely understood. For this a development of an in vitroscreening method to detect
drugs inside cells and map their mechanism of action and the cellular response is of critical
importance.
In the present work, Raman micro spectroscopy associated with multivariate data analysis
(PCA, PLSR and ICA) has been demonstrated to be capable of not only monitoring the
subcellular accumulation and distribution of the drug inside cells and elucidating the
mechanism of action, but also differentiating, as a function of time, the subsequent cellular
response. It is notable that the nucleolus is the first to be saturated by DOX and it is the first
cellular compartment to be affected and to react to this treatment, highlighting the importance
of this organelle in cancer development and in cancer therapy.
The profile of spectroscopic responses is complex, being a label free combinatorial response
of the affected biochemcial constituents in each region. Nevertheless, that profile is well
defined in terms of subcellular region and temporal evolution, indicating the potential of the
technique as an in vitro, pre-clinical screening technique for drug efficacy and mode of
action. Exploring differences in responses could ultimately elucidate meachnisms ofcellular
resistance, towards applications in companion diagnostics.
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